NMS-873

Catalog No.S7285 Batch:S728501

Print

Technical Data

Formula

C27H28N4O3S2

Molecular Weight 520.67 CAS No. 1418013-75-8
Solubility (25°C)* In vitro DMSO 100 mg/mL (192.06 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description NMS-873 is an allosteric and specific p97 inhibitor with IC50 of 30 nM that demonstrates potent selectivity for VCP/p97 compared to a panel of other AAA ATPases, Hsp90, and 53 additional analyzed kinases (IC50s >10 μM).
Targets
p97 [1]
(Cell-free assay)
30 nM
In vitro NMS-873 reduces p97 sensitivity to trypsin digestion, preventing degradation of the linker-D2 domain. NMS-873, as a p97 inhibitor, produces antiproliferative activity in a variety of hematological and solid tumor lines. The mechanism study indicates that NMS-873 activates the unfolded protein response, interfers with autophagy and thus induces cancer cell death. [1]
Features The most potent and specific p97 inhibitor described to date.

Protocol (from reference)

Kinase Assay:

[1]

  • Biochemical assay development and HTS

    The ATPase activity and the kinetic parameters of recombinant wild-type VCP and its mutants are evaluated by monitoring ADP formation in the reaction, using a modified NADH-coupled assay. As ADP and NADH are ATP-competitive inhibitors of VCP ATPase activity, the standard protocol for the NADH-coupled assay is modified into a two-step procedure. In the first part, an ATP-regenerating system (40 U/ml pyruvate kinase and 3 mM phosphoenolpyruvate) recycles the ADP produced by VCP activity, keeps the substrate concentration constant (thus preventing product inhibition) and accumulates a stoichiometric amount of pyruvate. In the second part, the VCP enzymatic reaction is quenched with 30 mM EDTA and 250 μM NADH and stoichiometrically oxidized by 40 U/ml lactic dehydrogenase to reduce accumulated pyruvate. The decrease of NADH concentration is measured at 340 nm using a Tecan Safire 2 reader plate. The assay is performed in 96- or 384-well UV plates in a reaction buffer with 50 mM Hepes, pH 7.5, 0.2 mg/mL BSA, 10 mM MgCl2 and 2 mM DTT. Experimental data are fitted with a cooperative equation obtaining a Ks* of about 60 μM and a Hill coefficient (n) of 2.0 ± 0.1. The HTS campaign is performed against a 1-million-compound library using a miniaturized assay in 1,536-well format and a more sensitive ADP detection system, Transcreener ADP FP. A 20-min preincubation of 10 nM VCP and 10 μM inhibitor is performed, after which 10 μM ATP is added to the reaction, which is allowed to proceed for 90 min before quenching. The average Z′ of the screening is 0.58, and the hit rate using 3× s.d. (38% inhibition) as cutoff is 1.7%. Primary hits with >60% inhibition at 10-μM concentration are pruned using physicochemical and structural filters to leave 7,516 compounds. At the end, reconfirmation is performed in duplicate on 3,988 primary hits, and 500 compounds are selected for a dose-response evaluation using the previously described NADH-modified coupled assay. The potency of the most interesting HTS hits is measured against both wild-type VCP and the C522T mutant. ATP concentrations that yielded the half-maximal velocity (Ks*) for each enzyme, corresponding to 60 μM and 130 μM for the wild type and C522T mutant, respectively, are used in the assay. To explore the dependency of reversible inhibitors from substrate concentration, their potency is evaluated also at saturating ATP concentration (1 mM) and compared to the potency of a standard ATP competitive inhibitor (AMP-PNP).

Cell Assay:

[1]

  • Cell lines

    A variety of hematological and solid tumor lines

  • Concentrations

    ~10 μM

  • Incubation Time

    72 hours

  • Method

    Cells are seeded at 1,600 cells per well in 384-well white clear-bottom plates. Twenty-four hours after seeding, cells are treated with the compounds (eight dilution points, in duplicate, for each compound) and incubated for an additional 72 h at 37 °C under a 5% CO2 atmosphere. Cells are then lysed, and the ATP content in each well is determined using a thermostable firefly luciferase–based assay as a measure of cell viability. IC50 values are calculated using the percentage of growth of treated cells versus the untreated control.

Customer Product Validation

, , Toxicol Appl Pharmacol, 2016, 305:267-73.

Selleck's NMS-873 has been cited by 44 publications

Replication fork uncoupling causes nascent strand degradation and fork reversal [ Nat Struct Mol Biol, 2023, 30(1):115-124] PubMed: 36593312
Replication fork uncoupling causes nascent strand degradation and fork reversal [ Nat Struct Mol Biol, 2023, 30(1):115-124] PubMed: 36593312
K6-linked ubiquitylation marks formaldehyde-induced RNA-protein crosslinks for resolution [ Mol Cell, 2023, 10.1016/j.molcel.2023.10.011] PubMed: 37951215
Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET [ Cell Death Differ, 2023, 10.1038/s41418-023-01167-4] PubMed: 37142656
Senescent cells form nuclear foci that contain the 26S proteasome [ Cell Rep, 2023, 42(8):112880] PubMed: 37541257
Proteomics Profiling Reveals the Molecular Signatures and Potential Therapeutic Targets of Human Nasopharyngeal Carcinoma [ Mol Cell Proteomics, 2023, 22(6):100567] PubMed: 37172717
Elucidating cellular interactome of chikungunya virus identifies host dependency factors [ Virol Sin, 2023, 38(4):497-507] PubMed: 37182691
p97/VCP drives turnover of SUMOylated centromeric CCAN proteins and CENP-A [ Molecular Biology of the Cell, 2023, 34(5)] PubMed: None
Regulation of membrane fluidity by RNF145-triggered degradation of the lipid hydrolase ADIPOR2 [ EMBO J, 2022, 41-19:e110777] PubMed: 35993436
Multiple Components of Protein Homeostasis Pathway Can Be Targeted to Produce Drug Synergies with VCP Inhibitors in Ovarian Cancer [ Cancers (Basel), 2022, 14(12)2949] PubMed: 35740614

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.